YouTube Facebook LinkedIn Google+ Twitter Xingrss  

Isis and Biogen Sign Six Year Collaboration


September 9, 2013 | Isis Pharmaceuticals signed a six-year agreement with Biogen Idec to develop new therapies to treat neurological disorders. Isis is eligible to receive $100 million in milestone payments, license fees, and royalty payments. Bloomberg Businessweek
Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

For reprints and/or copyright permission, please contact  Jay Mulhern, (781) 972-1359, jmulhern@healthtech.com.